Differential survival outcomes between de novo and secondary Acute Promyelocytic Leukemia: An updated population-based study
Whether the characteristics and outcome of secondary acute promyelocytic leukemia (s-APL) are similar to de no APL (dn-APL) remains unknown. Using the SEER database, we identified 3877 patients with APL diagnosed from 2000-2014, including 465 s-APL and 3412 dn-APL. Compared with dn-APL, s-APL were characterized by older median age and a higher early mortality rate. Multivariate Cox model showed s-APL, older age, earlier year of diagnosis, and male gender were independently associated with worse survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 4, 2021 Category: Hematology Authors: Yi Tao, Ya-Qin Yu, Yuan-Yuan Liu, Mengyu Jia, Lu Gao Source Type: research

Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study)
Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the characteristics, clinical management and outcome of CLL patients receiving ibrutinib in routine clinical practice in Spain. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 3, 2021 Category: Hematology Authors: Pau Abrisqueta, Javier Loscertales, Maria Jos é Terol, Ángel Ramírez Payer, Macarena Ortiz, Inmaculada Pérez, Carolina Cuellar-García, Margarita Fernández de la Mata, Alicia Rodríguez, Ana Lario, Julio Delgado, Ana Godoy, José Mª Arguiñano Pére Tags: Original Article Source Type: research

On behalf of the SFGM-TC: retrospective comparison of reduced and higher intensity conditioning for high-risk myelodysplastic syndrome treated with allogeneic stem-cell transplantation
Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) remains the best curative option for high-risk myelodysplastic syndrome (MDS). We retrospectively compared patient outcomes after allo-HSCT according to the intensity of the conditioning regimen. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Arnaud Campidelli, Marie Robin, Thomas Remen, Amandine Luc, H élène Labussière-Wallet, Rémi Dulery, Micha Srour, Patrice Ceballos, Edouard Forcade, Stephanie Nguyen-Quoc, Sabine Furst, Pascal Turlure, Jacques-Olivier Bay, Célestine Simand, Ambroise M Source Type: research

Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care
Multiple myeloma (MM) is a hematological cancer associated with significant symptomatic burden. Bone disease, renal insufficiency, cytopenias, infection, and peripheral neuropathy, among other disease manifestations and complications, impair patients ’ quality of life.The Canadian Myeloma Research Group Consensus Guideline Consortium (CMRG-CGC), formerly Myeloma Canada Research Network Consensus Guideline Consortium, proposes national consensus recommendations for the management of MM-related manifestations and complications. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Richard LeBlanc, Debra J. Bergstrom, Julie C ôté, Rami Kotb, Martha L. Louzada, Heather J. Sutherland, Hira S. Mian, Ibraheem Othman, Anthony Reiman, Irwindeep Sandhu, Sofia Tavoularis, Christopher P. Venner, Darrell J. White, Gabriele Colasurdo, David Source Type: research

A Phase 2 Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
This study evaluated venetoclax with pomalidomide and dexamethasone (VenPd) in RRMM.Patients and Methods: This phase 2 open label study (NCT03567616) evaluated VenPd in patients with RRMM who had received ≥1 prior therapy and were refractory to lenalidomide. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Cristina Gasparetto, Kristian M. Bowles, Al-Ola Abdallah, Lura Morris, Gudrun Mander, Sheryl Coppola, Jing Wang, Jeremy A. Ross, Orlando F. Bueno, Emma Arriola, Maria Victoria Mateos Source Type: research

Multiple Myeloma: Risk adapted use of plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient
Background: We used plerixafor in ‘a risk adapted approach’ for stem cell mobilization for multiple myeloma (MM) patients prior to autologous stem cell transplantation (ASCT).Patients and Methods: Between January, 2017 and December, 2019 one hundred and five consecutive patients of MM were recruited (Study Cohort). Patients rece ived inj G-CSF 10 µg/kg in 2 divided doses for 5 days. Day 4 peripheral blood (PB) CD34+ count was used as a guide; if count was (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Vadlamani Surya Prakash, Prabhat Singh Malik, Ranjit Kumar Sahoo, Raja Pramanik, Priyanshu Choudhary, Ankur Nandan Varshney, Lalit Kumar Source Type: research

Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy/edema, monoclonal plasma protein [M protein], and skin changes) is a rare paraneoplastic disorder associated with underlying plasma cell neoplasia. Although limited-stage disease can be treated with radiotherapy, treatment for the more advanced disease remains unclear. The most commonly used therapies for POEMS syndrome include alkylators and steroids, high-dose chemotherapy with autologous stem cell transplantation, lenalidomide, and bortezomib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Unaiza Faizan, Muhammad Khawar Sana, Muhammad Saad Farooqi, Hamza Hashmi Source Type: research

Myelodysplastic Syndromes: A New Decade
Myelodysplastic syndromes are a group of heterogeneous clonal hematopoietic stem cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates the incidence rate of MDS increases with age especially in those greater than 70 years of age. Risk stratification that impact prognosis, survival, and rate of AML transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supplement.Low risk MDS typically have a more indolent disease course in which treatment is only initiated to ameliorate symptoms of cytopenias. (Source: Clinical...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Virginia O. Volpe, Guillermo Garcia-Manero, Rami S. Komrokji Source Type: research

"Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease".
In recent years, the life expectancy of Multiple Myeloma (MM) patients has substantially improved, but this cancer remains incurable with increasing incidence in the developed world. Most MM patients will eventually relapse due to residual drug-resistant cancerous cells that survive treatment, commonly referred to as minimal residual disease (MRD). Methods to improve MRD detection in MM patients are generating considerable interest as a means of monitoring patients' response to treatment. In clinical laboratories, these methods currently require bone marrow aspirates which are invasive and frequently miss detection of loca...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Dr. Aisling O'Brien Source Type: research

Perceptions of Role in Treatment Decision Making and Understanding of Late Effects among Hodgkin Lymphoma Survivors: Results from a National Survey HL Decision Making and Late Effects
Background: Hodgkin Lymphoma (HL) survivors are at risk of treatment-related late effects (LEs). With these potential risks and increasing numbers of treatment options for newly diagnosed patients, communication and shared decision making are essential to supporting patients throughout the cancer care continuum. We aimed to gather perspectives of HL survivors about their actual role in treatment decision making and their understanding of LEs.Methods: After initial pilot testing at a cancer survivor conference, we disseminated a 23-question survey in a single-wave e-mail through the Leukemia& Lymphoma Society's national...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Anita J Kumar, Rachel Murphy-Banks, Ruth Ann Weidner, Susan K Parsons Source Type: research

An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma
Background: Doxorubicin carries a risk of congestive heart failure (CHF). Black race has been suggested as a risk factor for doxorubicin-related cardiotoxicity, but data are limited. We assessed whether HF occurs at higher rates in Black patients compared to White patients who receive doxorubicin for DLBCL, and evaluated race as an independent risk factor for the development of HF after adjusting for known risk factors.Patients and Methods: We used SEER-Medicare to identify patients 66 years and older with DLBCL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 2, 2021 Category: Hematology Authors: Ahmed Toure, Danny Luan, Yiyuan Wu, Paul J Christos, John P Leonard, Peter Martin Source Type: research

Dealing with high-risk AL Amyloidosis patients: a single hematologic Center Experience.
Immunoglobulin light chain (AL) amyloidosis is a disease hematological in nature that requires thoughtfully selected hematological therapies. However, the main clinical manifestations very rarely involve the hematopoietic system and are so subtle and deceptive which require to be managed by a few experienced centers. The heart and kidney are the two most frequently affected organs, and the outcome is heavily related to the degree of heart involvement 1. The Revised (2012) Mayo Clinic staging system identifies patients at stage I, II, III, and IV with median overall survival (OS) of 94.1, 40.3, 14, and 5.8 months, respectiv...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 28, 2021 Category: Hematology Authors: Marcello Riva, Tamara Berno, Alberto Cipriani, Sara Altinier, Marny Fedrigo, Franco Noventa, Fausto Adami Source Type: research

Efficacy and Safety of Azacytidine in combination with fludarabine and high-dose cytarabine with G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Relapsed and refractory adult acute myeloid leukemia (AML) is a challenging disease to treat with poor outcomes. There is no standard treatment for the AML in those settings, and incorporating new strategies is urgently needed. In AML, aberrant DNA methylation has been strongly associated with progression, relapse, and drug resistance. 1-3 These studies endorse the rationale to combine hypomethylating agents (HMAs), such as azacytidine (AZA), with high-intensity chemotherapy. At a low dose, HMAs act as DNA methyltransferase inhibitors (DNMTis), inducing global DNA hypomethylation, thereby activating tumor suppressors, down...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 28, 2021 Category: Hematology Authors: Ibraheem H. Motabi, Shaima M. Al Aoun, Maged Al-Ammari, Belal M. Albtoosh, Shahid Iqbal, Syed Y. Altaf, Imran K. Tailor, Mohammed S. Alnoamani, Mubarak S. AlGhamdi, Syed ZA Zaidi, Nawal F. AlShehry, Mohammed A. Marei, Mansour Alfayez Source Type: research

Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country
Few cancer centers from developing countries have described the impact of COVID-19 on pediatric cancer patients. Seventy-six pediatric oncology patients with COVID-19 infection were recruited. Most patients had a favourable outcome with sixty-day overall survival of 86.8%. Mortalities occurred only among patients with critical forms of infection. The potential benefits  of remdesivir in pediatric oncology patients require further studies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 26, 2021 Category: Hematology Authors: Mahmoud Hammad, Lobna Shalaby, Iman Sidhom, Nancy Sherief, Ibrahim Abdo, Sonia Soliman, Youssef Madeny, Reem Hassan, Shaimaa Elmeniawy, Nagwa Khamis, Iman Zaki, Tarek Mansour, Mohamed Gamal El-Ansary, Ahmed El-Halfawy, Sherif Abouelnaga, Alaa Elhaddad Source Type: research

IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era
: Part B of the modified Magrath regimen (IVAC) +/- rituximab (R) is recommended as standalone therapy by national guidelines for management of relapsed/refractory Burkitt lymphoma, and is used in other non-Hodgkin lymphomas (NHL). Activity of IVAC in B-cell NHL, particularly with R, and its toxicity remain incompletely described. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2021 Category: Hematology Authors: Michael J. Buege, Phuong H. Dao, Esther Drill, Andr éa LeVoir, Terry Pak, Tim J. Peterson, David J. Straus Source Type: research

Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
PNT2258 is a liposomal formulation that encapsulates multiple copies of PNT100, a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the B-cell lymphoma 2 (BCL2) gene. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2021 Category: Hematology Authors: Jason Westin, Michael B Maris, Caron A Jacobson, Prapti Patel, Nehal Lakhani, Wael Harb, Dipti Patel-Donnelly, Kelly McCaul, Carolina Escobar, Barbara Klencke, Ayad M. Al-Katib Source Type: research

Primary cutaneous B-cell lymphomas in children and adolescents: a SEER population-based study
The overall incidence of primary cutaneous lymphomas is approximately 10.7 per 1,000,000 person ‐years,1 with 5% occurring in children and adolescents. Cutaneous lymphomas can be broadly divided into primary cutaneous T-cell lymphoma (PCTCL) or primary cutaneous B-cell lymphoma (PCBCL). According to the WHO–European Organization for Research and Treatment of Cancer (WHO–EORTC), PCBCL is further classified into three major subtypes: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2021 Category: Hematology Authors: David Bomze, Eli Sprecher, Ilan Goldberg, Liat Samuelov, Shamir Geller Source Type: research

AGE, BLASTS, PERFORMANCE STATUS AND LENALIDOMIDE THERAPY INFLUENCE THE OUTCOME OF MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5q): A STUDY OF 58 SOUTH AMERICAN PATIENTS
This study analyzed the overall survival (OS) of patients with Myelodysplastic Syndrome (MDS) with isolated deletion 5q in South America. Age>75 years, ECOG ≥2 and BM blasts>2% at diagnosis are independently associated with worse OS. Lenalidomide treatment is the only factor that improves the OS.Background: Myelodysplastic Syndrome (MDS) with isolated deletion 5q is associated with a low risk to leukemic evolution and long overall survival (OS); it comprises 3-4.5% of MDS cases in Latin America classified according to the WHO 2008. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2021 Category: Hematology Authors: RS Azevedo, C Belli, L Bassolli, L Ferri, MA Perusini, A Enrico, TDM Pereira, WFS Junior, V Buccheri, RF Pinheiro, SM Magalhaes, S Schuster, JB Castelli, F Traina, V Rocha, EDRP Velloso Source Type: research

The effects of exercise prescription on aeorobic performance and quality of life during the course of lymphoma chemoterapy: results of a prospective controlled study
This study is designed to investigate the physical, psychological and quality of life (QoL) effects of a 16-week supervised and structured intensive aerobic and strength training during the first line chemotherapy of lymphomas. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2021 Category: Hematology Authors: Ugur Sahin, Ibrahim Dundar, Mehmet Mesut Celebi, Mustafa Merter, Esen Ismet Oktay, Ali Murat Zergeroglu, Muhit Ozcan Source Type: research

A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-cell Malignancies
PNT2258 consists of a native, chemically unmodified, 24-base DNA oligonucleotide designed to target the regulatory region upstream of the BCL2 gene, delivered in a protective liposome. Derangement of BCL2-regulated control mechanisms is a defining characteristic of certain malignancies, and it was hypothesized that the oligonucleotide would promote anticancer activity via suppression of BCL2 transcription. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2021 Category: Hematology Authors: Wael Harb, Nehal J. Lakhani, Richard Messmann, Barbara Klencke, Ayad M. Al-Katib Source Type: research

Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes
The SADAL study evaluated oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by DLBCL subtype to determine the effects of DLBCL subtypes on efficacy and tolerability of selinexor. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2021 Category: Hematology Authors: Rene-Olivier Casasnovas, George Follows, Josee M. Zijlstra, Joost S.P. Vermaat, Nagesh Kalakonda, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Source Type: research

Accurate Machine-Learning-Based classification of Leukemia from Blood Smear Images
Leukemia is a type of cancer, characterized by an anomalous production of immature, abnormally-shaped white blood cells (WBC) called “blasts”.1,2,3,4,5,6 Diagnosis is typically carried out by analyzing the white blood cells via the microscope of the blood smear.7 In a healthy adult, the ratio of red blood cells to white blood cell remains at 1000:1; and any value above this threshold is a characteristic, proliferative feature of leukemia in the patient.8,9,10,11 On the contarary, few cases of leukemic patients have also been diagnosed with lower white blood cell count. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 19, 2021 Category: Hematology Authors: Kokeb Dese, Hakkins Raj, Gelan Ayana, Tilahun Yemane, Wondimagegn Adissu, Janarthanan Krishnamoorthy, Timothy Kwa Source Type: research

Real-world experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience
Background: CD19-directed chimeric antigen T-cell receptor (CAR-T) therapies have revolutionized the treatment of patients with relapsed/refractory (R/R) aggressive B-cell lymphomas (aBCL). The results of the landmark ZUMA-1 and JULIET trials have been reproducible in real-world settings across multiple institutions, and patients with double (DHL) or triple (THL) hit lymphomas have demonstrated non-inferior outcomes compared to non-DHL/THL counterparts.Methods: This retrospective cohort study included 53 patients with R/R aBCL who received CAR-T from 10/2017-6/2020 at the University of California, Los Angeles (UCLA). (Sour...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 19, 2021 Category: Hematology Authors: Sanaz Ghafouri, Kathleen Fenerty, Gary Schiller, Sven de Vos, Herbert Eradat, John Timmerman, Sarah Larson, Monica Mead Source Type: research

Light chain amyloidosis (AL) associated with B cell lymphoma a single center experience.
Light chain (AL) amyloidosis and B ‐cell lymphoma represent 5–7% of all AL, Systemic amyloidosis, deposits in sites remote from the underlying lymphoma, and peritumoral amyloidosis deposition is within the immediate vicinity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 19, 2021 Category: Hematology Authors: Alfredo De la Torre, Donna Reece, Michael Crump, Eshetu G. Atenafu, Christine Chen, Anca Prica, Vishal Kukreti Source Type: research

Repertoire of rearranged immunoglobulin heavy chain genes in russian patients with b-cell lymphoproliferative diseases
IGHV repertoire narrowing could be an evidence for the involvement of a limited set of antigens in the development of lymphomas. For CLL the existence of more than 200 subgroups of tumor IGHV antigen-binding sites, so called “stereotypical” antigen receptors (SAR) has been shown. For others lymphomas the possibility of SARs is also suggested. The aim of this study is to compare the tumor IGHVs and possible SARs in various B-cell malignancies in Russia and other countries. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 19, 2021 Category: Hematology Authors: B.V. Biderman, E.B. Likold, S.Yu. Smirnova, E.A. Nikitin, D.A. Koroleva, E.E. Zvonkov, L.S. Al-Radi, H.L. Julhakyan, A.B. Sudarikov Source Type: research

Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections
Background: We previously reported elsewhere of a follicular lymphoma patient suffering from persistent COVID-19 pneumonia that was still ongoing at 2 months after onset. Materials and Methods: We provide a follow-up report of the case along with a literature review of immunocompromised lymphoma patients experiencing prolonged COVID-19 infections. Results: Although requiring a full 1 year, the presented case eventually achieved spontaneous resolution of COVID-19 pneumonia. Anti-SARS-CoV-2 antibodies could not be detected throughout the disease course, but COVID-19-directed T-cell response was found to be intact. (Source: C...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Hajime Yasuda, Yosuke Mori, Asako Chiba, Jie Bai, Goh Murayama, Yasushi Matsushita, Sachiko Miyake, Norio Komatsu Source Type: research

Long-term Outcome of Philadelphia Chromosome Positive Leukemia from Eastern Indian Sub-continent: An Experience in the Era of Tyrosine Kinase Inhibitor (TKI) Therapy
This study examined the features and long-term outcome of Ph+ve cases from a tertiary cancer care centre from Eastern Indian subcontinent. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Samya Dey, Debmalya Bhattacharyya, Partha Pratim Gupta, Somsubhra Nath Source Type: research

The Past, Present and Future of Venetoclax Plus Hypomethylating Agent Combination Therapies in AML
The use of venetoclax in combination with hypomethylating agents (HMA) has changed the paradigm for the treatment of acute myeloid leukemia (AML) in elderly patients and those unfit for intensive chemotherapy. A phase 3 study has shown superior response rates and improved overall survival for patients treated with venetoclax  + azacitidine compared with the previous standard of care, azacitidine alone. This success has led to multiple exciting follow-up studies, including investigations related to the discovery of predictors of response, relapse and the mechanism of action of this therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Anagha Inguva, Daniel A. Pollyea Source Type: research

Optimal Supportive Care with Selinexor Improves Outcomes in Patients with Relapsed/Refractory Multiple Myeloma
Multiple myeloma remains incurable despite the advent of more than ten new approved therapies within the last decade.1,2 Regardless of ongoing improvement in outcomes, patients with disease refractory to multiple lines of therapy have poor outcomes with survival rates of less than 6 months in patients refractory to daratumumab.3,4 Results from the pivotal STORM study, the largest trial to date in patients with myeloma refractory to proteasome inhibitors (PI), immunomodulatory drugs (IMiD), and daratumumab (i.e., triple-class refractory), showed that therapy with selinexor, a first-in-class, oral, selective exportin 1 (XPO1...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Ajai Chari, Erika Florendo, Ines Stefania Mancia, Hearn Cho, Deepu Madduri, Samir Parekh, Josh Richter, Amishi Dhadwal, Joanne Thomas, Grace Jiang, Alessandro Lagana, Sherry Bhalla, Sundar Jagannath Source Type: research

Frequency, clinical characteristics and outcome of adults with acute lymphoblastic leukemia and COVID 19 infection in the first vs. second pandemic wave in Spain
SARS-CoV-2 (COVID-19) infection has a negative impact on the outcomes of patients with cancer, with mortality rates over 20%.1-3 This is especially important in adults with hematologic neoplasias and in those submitted to allogeneic hematopoietic stem cell transplant (HSCT), in whom the death rate is over 30%4-8 compared to 4% in children.4 Patients with active disease and those receiving intensive chemotherapy or immunotherapy are especially vulnerable. Apart from the cancer itself other factors such as advanced age, poor general status and neutropenia contribute to this high mortality rate. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Josep-Maria Ribera, Mireia Morgades, Rosa Coll, Pere Barba, Jose-Luis L ópez-Lorenzo, Pau Montesinos, María-Angeles Foncillas, Mónica Cabrero, Ignacio Gómez-Centurión, María-Dolores Morales, María-Rosario Varela, Pilar Herrera, Irene García-Cadena Source Type: research

Late Responses in Patients with Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors
The introduction of tyrosine kinase inhibitor (TKI) therapy has dramatically improved outcomes for patients with chronic myeloid leukemia (CML); however, the prognosis for those who do not meet treatment milestones remains guarded. Here, we report our experience of patients with CML treated at a single center who did not achieve a complete cytogenetic response (CCyR) at 24 months. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Justin Shaya, Kristen Pettit, Malathi Kandarpa, Dale Bixby, Jessica Mercer, Moshe Talpaz Source Type: research

Special Considerations for Supportive Care and Management of Complications in Elderly Patients with Multiple Myeloma
Multiple Myeloma (MM) was first well documented in 1844 (1). Recent studies have shown that the 5-year survival rate for MM has increased to 49% from roughly 25% (2). Despite this, elderly patients experience fewer of these benefits relative to younger patients (3). Due to the progressive and incurable nature of MM, along with advancing age, patients ultimately develop worsening end-organ complications. MM patients have a statistically significant lower quality of life (QOL) than the general population, commonly citing physical symptoms like pain, fatigue, as well as financial strain and fear of dying (4). (Source: Clinica...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Laeth L. George, Mustafa N. Malik, Eric J Miller, Kayla Hicks, Razwana Khanam, Alireza Saterehaseman, Megan McNichol, Faiz Anwer Source Type: research

Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia
The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality. We identified 84 ALL patients 70-84 years old allografted in 2002-2019 from a matched related (23%), unrelated (58%), haploidentical (17%) or cord blood (2%) donor at EBMT participating centers with a median follow-up of 23 months. (Source: Clinical Lymphoma, ...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 16, 2021 Category: Hematology Authors: Abdul Hamid Bazarbachi, Myriam Labopin, Nicolaus Kr öger, Arne Brecht, Didier Blaise, Johannes Clausen, Renato Fanin, Herman Einsele, Luigi Cavanna, Maija Itäla-Remes, Claude Eric Bulabois, Lukas Kündgen, Hans Martin, Christof Schmid, Eva Maria Wagner- Source Type: research

Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients
Acute myeloid leukemia (AML) is one of the rapidly progressing malignancies which is characterized by unregulated proliferation of hematopoietic precursors .Technological improvements enhanced the availability of genetic AML biomarkers. The clinical relevance of these molecular markers for AML diagnosis, planning of therapy and risk stratification are increasing evidently. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 15, 2021 Category: Hematology Authors: Heba Allah E Abd Elrhman, Yomna M El-Meligui, Saffaa M Elalawi Source Type: research

SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia
A wider use of L-asparaginase in the treatment of children with acute lymphoblastic leukemia has improved cure rates during recent decades and hence led to introduction of pediatric-inspired treatment protocols for adolescents and young adults. In parallel, a range of burdensome, often severe and occasionally life-threatening toxicities have become frequent, including hypersensitivity, hepatotoxicity, hypertriglyceridemia, thromboembolism, pancreatitis, and osteonecrosis. This often leads to truncation of asparaginase therapy, which at least in the pediatric population has been clearly associated with a higher risk of leuk...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 15, 2021 Category: Hematology Authors: Kjeld Schmiegelow, Cecilie Utke Rank, Wendy Stock, Emily Dworkin, Inge van der Sluis Source Type: research

Carfilzomib-induced atypical hemolytic uremic syndrome in a patient with heterozygous, CFHR3/CFHR1 deletion treated with eculizumab
Thrombotic microangiopathy (TMA) encompasses a collection of syndromes characterized by endothelial injury, microangiopathic hemolytic anemia (MAHA) and organ failure. Atypical hemolytic uremic syndrome (aHUS) is a subtype of TMA related to excessive alternative complement pathway activation and typically presents with acute renal failure in addition to the aforementioned features of TMA. Patients may also present with cardiovascular, respiratory, or neurologic symptoms in addition to multiorgan dysfunction. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 14, 2021 Category: Hematology Authors: Craig W. Freyer, Erin M. Bange, Sarah Skuli, Miles Hsu, John Lin, Adam Cuker, Adam D. Cohen, Alfred Garfall Tags: Clinical Lymphoma, Myeloma and Leukemia Source Type: research

The real-life efficacy of fixed-dose hypomethylating agents in older patients with acute myeloid leukemia: A 10-year experience
This study focuses on the clinical outcome of various treatment protocols, including intensive chemotherapy, fixed-dose HMAs, and palliative treatment in Thai elderly patients with AML. Fixed-dose HMAs include 5-azacitidine given at 100 mg per day for seven days and decitabine given at 30 mg per day for five days. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 14, 2021 Category: Hematology Authors: Tarinee Rungjirajittranon, Smith Kungwankiattichai, Chutima Kunacheewa, Weerapat Owatthanapanich Source Type: research

Molecular characterization and clinical treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients with TP53 mutation
Mutations in TP53 in myeloid neoplasms patients have been associated with poor prognosis. Effective treatments to these patients remain unclear. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 12, 2021 Category: Hematology Authors: Yanfen Li, Hua Wan, Yu Jing Source Type: research

Outcomes related to FDG-PET-CT response in patients with Hodgkin Lymphoma treated with brentuximab-vedotin at relapse or consolidation
: Brentuximab-vedotin (BV) monotherapy has shown high efficacy in heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma (HL) after high-dose chemotherapy or autologous stem cell transplantation (ASCT).  We retrospectively analyzed the outcomes of treatment with BV of HL patients and examined the predictive ability of PET-CT for response in this setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 12, 2021 Category: Hematology Authors: Meirav Kedmi, Pavel Khaustov, Elena Ribakovsy, Ohad Benjamini, Abraham Avigdor Source Type: research

The role of interim pet/ct on survival in diffuse large b cell lymphoma
In this study ve searched the association of interim PET on survival in 103 DLBCL patients .Interim PET assessed by 5 point Deauville Score predicts PFS and OS with a PPV of 65.4% and a NPV of 77.9 %. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 8, 2021 Category: Hematology Authors: Meral U. Ulukoylu Menguc, Ozgur Mehtap, G özde Daglıoz Gorur, Elif Birtas Atesoglu, Ayfer Geduk, Serkan Unal, Pınar Tarkun, Abdullah Hacıhanefioglu Source Type: research

Clinical Outcomes of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System
: Healthcare disparities persist in ALL despite therapeutic advances and improved outcomes at specialized centers. Our retrospective cohort analysis describes outcomes of 146 newly-diagnosed ALL patients treated in the safety-net hospital of the third-most-populous US county. Addressing social factors limiting access to health care; adopting effective, less-costly therapies; and improving clinical trial patient diversity may improve outcomes among underserved populations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 4, 2021 Category: Hematology Authors: Effrosyni Apostolidou, Curtis Lachowiez, Harinder Juneja, Wei Qiao, Onye Ononogbu, Courtney Miller-Chism, Mark Udden, Hilary Ma, Martha Mims Source Type: research

Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea
Polycythemia vera (PV) is a Philadelphia chromosome-negative chronic myeloproliferative neoplasm affecting more than 100,000 people in the United States.1 The disease is characterized by an abnormal increase in red cell mass and the presence of JAK2 V617F or JAK2 exon 12 mutations.2 Patients with PV are at risk for thromboembolic events (TEs), premature death, and burdensome symptoms.3-5 The goals of PV therapy are to prevent TEs and hemorrhagic complications and to manage disease-related symptoms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 4, 2021 Category: Hematology Authors: Ivy Altomare, Shreekant Parasuraman, Dilan Paranagama, Jonathan Kish, Kevin Lord, Jingbo Yu, Philomena Colucci Source Type: research

A prospective economic analysis of early outcome data from the Alliance A041202/ CCTG CLC.2 randomized  phase III trial of bendamustine-rituximab compared with ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia
: The Alliance A041202/ CCTG CLC.2 trial demonstrated superior progression-free survival with ibrutinib-based therapy compared to chemoimmunotherapy in chronic lymphocytic leukemia. A trial-based economic analysis was conducted to determine the associated direct medical costs and quality-adjusted benefit. Total mean costs (over 2-years) were substantially higher for ibrutinib-based therapy while quality-adjusted survival was similar between treatment arms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 3, 2021 Category: Hematology Authors: Matthew C. Cheung, Nicole Mittmann, Carolyn Owen, Nizar Abdel-Samad, Graeme A.M. Fraser, Selay Lam, Michael Crump, Catherine Sperlich, Richard van der Jagt, Anca Prica, Stephen Couban, Jennifer A. Woyach, Amy S. Ruppert, Allison M. Booth, Sumithra J. Mand Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 1, 2021 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 1, 2021 Category: Hematology Source Type: research

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
Combining oral PI3K inhibitors with immunochemotherapy for indolent B-cell lymphoma has been associated with toxicity. In the Phase III CHRONOS-4 safety run-in, 21 patients received intravenous copanlisib plus rituximab-based immunochemotherapy. There were no dose-limiting toxicities, and preliminary objective response rates were 90-100%. Copanlisib is the first PI3K inhibitor to demonstrate safe, tolerable, and effective combinability with immunochemotherapy, with evaluation ongoing. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 1, 2021 Category: Hematology Authors: Matthew J. Matasar, Martin Dreyling, Sirpa Lepp ä, Armando Santoro, Michael Pedersen, Viktoriya Buvaylo, Monique Fletcher, Barrett H. Childs, Pier Luigi Zinzani Source Type: research

Ninety-minute Daratumumab infusions for relapsed and refractory multiple myeloma: two years of Italian single-centre observational study
Daratumumab was the first fully human anti-CD38 monoclonal antibody (mAb) to be tested in clinical trials1, demonstrating efficacy as a single agent in patients with relapsed/refractory multiple myeloma (RRMM). Daratumumab exerts direct anti-tumor and indirect immunomodulatory effects by targeting CD38, a cell surface receptor highly expressed on neoplastic plasma cells2,3. Daratumumab was first approved in patients with RRMM as monotherapy4 and subsequently in combination with proteasome inhibitors (PIs, Dara-VD)5,6 or immunomodulatory drugs (IMiDs, Dara-RD)7; currently, it is employed also for the treatment of newly diag...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 27, 2021 Category: Hematology Authors: Enrico Attardi, Sofia Pilerci, Irene Attucci, Alessandra Buzzichelli, Maria Messeri, Michela Staderini, Alessandro M Vannucchi, Elisabetta Antonioli Tags: Letter to the editor Source Type: research

Panobinostat from bench to bedside: rethinking the treatment paradigm for multiple myeloma
While novel agents have improved outcomes in multiple myeloma (MM),1 –3 nearly all patients eventually relapse on a given regimen and require new treatment options.4 Therapies are needed to overcome acquired resistance to prior therapies and to enhance response to therapy, particularly in patients with high-risk cytogenetic abnormalities or other high-risk disease characteristics.1 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 26, 2021 Category: Hematology Authors: Jesus G. Berdeja, Jacob P. Laubach, Joshua Richter, Steve Stricker, Andrew Spencer, Paul G. Richardson, Ajai Chari Source Type: research

A case of Bing-Neel syndrome treated successfully with ibrutinib monotherapy following intensive chemoimmunotherapy
The Bing-Neel syndrome (BNS) is a rare clinicopathological entity which refers to central nervous system (CNS) localization by lymphoplasmacytic lymphoma.1 Jens Bing and Axel Valdemar Neel in 1936 for the first time reported the presence of neurological symptoms in patients with hyperglobulinemia and no evidence of myeloma.2,3 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 25, 2021 Category: Hematology Authors: Matteo Carella, Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Pier Luigi Zinzani Tags: Case Report Source Type: research

Diffuse Large B Cell Lymphoma in patients 80 years and older: Worse Survival After Treatment Without Increased Relapse Rates.
Age is an adverse prognostic factor in diffuse large B cell lymphoma (DLBCL), but there are limited data on the outcomes of patients ≥ 80 years, including those treated with dose reduced chemoimmunotherapy. We conducted a retrospective analysis of 542 patients, 85 (16%) were ≥ 80 years of age. Although this very elderly group had more frequent comorbidities and decreased performance status, 89% received therapy. Four-year PFS was 42% vs. 61% (p (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2021 Category: Hematology Authors: Madison Keenan, Akiva Diamond, Kirsten Boughan, Brenda Cooper, Molly Gallogly, Ehsan Malek, Leland Metheny, Timothy O'Brien, Folashade Otegbeye, Benjamin Tomlinson, Marcos de Lima, Paolo F. Caimi Source Type: research